Silo Pharma (SILO) announced that the U.S. Patent and Trademark Office, USPTO, had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 that Silo licenses from Columbia University. The to-be-issued patent will further strengthen Silo’s IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder. The patent is expected to issue as U.S. Patent No. 12,329,726 on June 17, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma board approves purchase of bitcoin as treasury reserve
- Psychedelic: atai Life Sciences reports Phase 2a study data on BPL-003
- Silo Pharma, Resyca partner for intranasal drug-device study of SPC-15
- Silo Pharma Completes Public Offering, Raises $1.56 Million
- Silo Pharma prices 3.3M shares at 60c in public offering
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue